Healthcare artificial intelligence company Qure.ai gets its second clearance from the Food and Drug Administration (FDA) of the United States for its brain CT scan artificial intelligence quantification product qER-Quant.
This new technology will help doctors to quickly and accurately diagnose patients’ severity of conditions like hemorrhagic stroke, traumatic brain injury, and hydrocephalus. Doctors now will be able to track their patients’ pathological progression over time.
As CT scan is the standard diagnostic procedure for assessing brain injuries, this artificial intelligence will definitely benefit individual doctors and hospitals to treat their patients in a better and more efficient manner.
Read More: US senators send Letter to Amazon CEO due to Privacy concerns
Founder and research & development head of Qure.ai. Dr. Pooja Rao said, “This FDA clearance adds quantification, outlining and measurement capabilities to Qure.ai’s first clearance for triage and notification of critical brain abnormalities. We are excited about bringing a complete suite of capabilities to clinicians who deal with critical head CT scans.”
The new artificial intelligence technology of Qure.ai will enable doctors to make informed decisions that will considerably reduce diagnostic errors. Mumbai-based health tech startup Qure.ai was founded by Prashant Warier and Pooja Rao in the year 2016.
The company specializes in developing deep learning and artificial intelligence solutions to aid physicians with diagnosis and routine treatments of patients. The firm has received a total funding of $16 million till date from investors like Sequoia Capital India and MassMutual Ventures Southeast Asia.
CEO of Qure.ai, Prashant Warier, said, “We’ve always built products to solve real customer challenges, and qER Quant is another example of the same. We worked on this capability based on customer feedback from radiologists, neurologists, and ER physicians who expressed the need to get automated volume measurements on neuro scans to assess patient progress as well as safe discharge decisions.”
He further added that this new development would help the company to offer a comprehensive suite of AI tools for doctors.
